Compare ROK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROK | ARGX |
|---|---|---|
| Founded | 1903 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 50.4B |
| IPO Year | 1987 | 2017 |
| Metric | ROK | ARGX |
|---|---|---|
| Price | $423.81 | $843.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $415.77 | ★ $979.22 |
| AVG Volume (30 Days) | ★ 659.0K | 402.2K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 7.67 | ★ 23.27 |
| Revenue | ★ $8,342,000,000.00 | $3,683,281,000.00 |
| Revenue This Year | $7.12 | $91.44 |
| Revenue Next Year | $5.82 | $36.90 |
| P/E Ratio | $54.09 | ★ $33.83 |
| Revenue Growth | 0.94 | ★ 92.98 |
| 52 Week Low | $215.00 | $510.06 |
| 52 Week High | $429.58 | $934.62 |
| Indicator | ROK | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 59.85 | 53.22 |
| Support Level | $413.71 | $810.52 |
| Resistance Level | $429.58 | $881.89 |
| Average True Range (ATR) | 8.14 | 20.92 |
| MACD | 0.02 | 7.13 |
| Stochastic Oscillator | 83.34 | 64.93 |
With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.